Director, In Vitro (Obesity & Cardiometabolic Disease)

BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases.

We are seeking an experienced Director of In Vitro to lead the BioAge metabolic research team, with a focus on obesity and cardiometabolic diseases.

The Role: You will develop and manage research programs and align the technical teams around the company’s vision and strategy. This role will work closely with leaders across the company to plan and execute strategy, manage pipeline activities, and support the advancement of research programs throughout stages of research and development. This role reports to the Senior Vice President of Research.

You: You will bring significant experience and a proven track record of success in this therapeutic area, as well as a deep understanding of the state of the art in drug discovery and development, including molecular biology methods and bioinformatic tools.

Essential Job Duties:

• Provide subject matter expertise for maturation of later stage development programs, including molecular understandings and therapeutic areas
• Define and direct efforts to screen therapeutic interventions against new targets related to obesity and cardiometabolic diseases, as well as collaborating with technology teams to evaluate and develop improvements in therapeutic approaches
• Stay up to date and drive implementation of new in vitro and molecular biology technologies in obesity and related fields
• Utilize outsourcing strategically to achieve objectives, especially in specialized areas of obesity and cardiometabolic development.
• Coach and mentor team members across multiple levels of reporting to nurture and expand perspective and rigor to experiments and strategy

Required Skills and Abilities

• Strong leadership in driving research with a focus on obesity and cardiometabolic diseases.
• Proven track record in managing cross-functional teams and external vendors, ensuring the integration and quality of obesity and cardiometabolic research.
• Expertise in the development, standardization, and implementation of assays, particularly in the context of obesity and cardiometabolic diseases.
• Exceptional mentoring and team management skills, with the ability to lead teams focusing on obesity and cardiometabolic biomarker research.
• Strategic thinking and the ability to manage resources effectively, ensuring the alignment of research with the company’s strategic objectives in obesity and cardiometabolic drug development.
• Strong communication skills, capable of articulating complex scientific concepts and results to a diverse range of stakeholders.

Minimum Qualifications:

• Ph.D. degree in Life Sciences is required 10+ years of relevant biotech/pharmaceutical experience in cardiometabolic research
• Leadership experience with the capacity to build, develop, and lead teams, both as a manager and cross-functionally through the organization
• In-depth knowledge of cardiometabolic systems and the ability to distill insights from complex molecular datasets (e.g., sequencing data, functional assays, etc.) is essential
• Familiarity with regulatory submissions and strong technical writing skills are expected
• Superior oral presentation and written communication skills
• Ability to work collaboratively with a wide variety of internal and external constituencies
• Ability to work with minimal direction and be flexible
• Strategic vision and ability to tie together program and business goals
• Ability to foster and contribute to a culture of excellence grounded in problem solving and teamwork
• Ability to prioritize and to manage complexity

Our company

BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. The company’s lead program, azelaprag, is a potential first-in-class oral APJ agonist entering Phase 2 trials in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge’s preclinical programs address key pathways in metabolic aging, based on novel insights from its discovery platform built on human longevity data. To date, BioAge has raised more than $300 million from a top-tier syndicate of investors and pharma companies.

Our workplace

BioAge offers competitive salary, a comprehensive compensation package, and generous paid time off in addition to company-observed holidays. We provide comprehensive health and wellness benefits (medical, dental, and vision insurance) and a 401(k) retirement savings plan with matching employer contributions, and we support families through childcare and fertility benefits. We also pride ourselves in giving employees many opportunities for career development, including a generous annual budget for continued learning and a dedication to training and skill development. The salary for this role is expected to be approximately $175,000 - $250,000 for someone who meets all of the minimum qualifications as listed for the role, and may be adjusted accordingly for someone with more or less experience as a Director or Senior Director. We are open to the concept that different experience levels add value to the team in different ways, and therefore will consider a variety of experience and offer commensurate pay.

At BioAge, we embrace diversity and differences while we learn from each other, and we believe that every team member has an important role to play. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as to the letter of all applicable laws and regulations.